NASDAQ · TEM
Tempus AI, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TEM: Nov 02, 2026
Tempus AI, Inc. Class A Common Stock is expected to report earnings on 11/02/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.32. The reported EPS for the same quarter last year was $-0.31.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.32 | $-0.22 | $-0.38 | 4 |
| Dec 2026 | $-0.27 | $-0.12 | $-0.37 | 4 |
| Mar 2027 | $-0.39 | $-0.27 | $-0.50 | 2 |
| Jun 2027 | $-0.35 | $-0.25 | $-0.45 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · BNK Invest- Zacks · Oct 28, 9:00 AM EDTEarnings Preview: Schrodinger, Inc. (SDGR) Q3 Earnings Expected to DeclineSchrodinger (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 26, 9:00 AM EDTTempus AI (TEM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Tempus (TEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 23, 11:26 AM EDTBristol Myers Squibb Moves On Two Fronts: MS Cell Therapy Data And Tempus AI Expansion; Stock Down(RTTNews) – Bristol Myers Squibb (BMY) presented interim results from the Phase 1 Breakfree-2 study of investigational zolacabtagene autoleucel (zola-cel) in patients with highly active relapsing and progressive multiple sclerosis (MS) at MSToronto 2026.
- BNK Invest · Oct 22, 10:51 AM EDTAGIX, CRCL, TWLO, TEM: Large Outflows Detected at ETFLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the KraneShares Artificial Intelligence and Technology ETF (Symbol: AGIX) where we have detected an approximate $302.1 million dollar outflow — that's
- Zacks · Oct 21, 9:16 AM EDTNatera Partners With TransCode to Advance Colorectal Cancer TrialNTRA partners with TransCode Therapeutics to use Signatera MRD testing in a Phase 2a colorectal cancer trial, aiming to accelerate enrollment and research.
- Zacks · Oct 19, 9:00 AM EDTHere's How Tempus AI Demonstrates Improving Operating LeverageTEM shows improving operating leverage as Q2 revenues jump 22%, adjusted EBITDA turns positive and lower interest costs support its free cash flow goal.
- RTTNews · Oct 13, 8:47 AM EDTTempus AI's Ambry Genetics Launches GenomeNext To Improve Rare Disease Diagnosis(RTTNews) – Tempus AI, Inc. (TEM) announced that its wholly owned subsidiary, Ambry Genetics, has launched GenomeNext and GenomeReveal, a comprehensive whole genome sequencing solution designed to improve diagnosis for patients with rare diseases.
- Zacks · Oct 12, 10:46 AM EDTTempus AI Expands Strategic Collaborations to Drive Future GrowthTEM is expanding its precision medicine footprint through strategic collaborations with Moderna, Merck and Recursion, paving the way for future revenue growth.
- Zacks · Oct 9, 8:51 AM EDTShould You Buy, Hold or Sell Tempus AI Stock Amid AI Boom?TEM's strong data licensing growth, AI-driven innovations and rising shares favor holding the stock, but premium valuation and reimbursement risks warrant caution.
- BNK Invest · Oct 6, 3:20 PM EDTNoteworthy Tuesday Option Activity: HTZ, TEM, OKLOAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Hertz Global Holdings Inc (Symbol: HTZ), where a total of 113,948 contracts have traded so far, representing approximately 11.4 million underlying shares. That amounts t
- Zacks · Oct 5, 10:03 AM EDTHere's How Tempus AI is Capitalizing on AI-ECG Market GrowthTEM is expanding its cardiovascular portfolio with FDA-cleared AI-ECG tools targeting complex cardiac conditions.
- RTTNews · Oct 2, 12:13 PM EDTWeekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data(RTTNews) – The week brought a fresh round of developments across the biotech and pharma landscape, with companies advancing new therapies through regulatory milestones, clinical studies, strategic deals and corporate activity. Key updates spanned oncology, rare diseases, cardiov
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Tempus AI, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.